These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 27070547)

  • 1. Novel HIV-1 Non-nucleoside Reverse Transcriptase Inhibitor Agents: Optimization of Diarylanilines with High Potency against Wild-Type and Rilpivirine-Resistant E138K Mutant Virus.
    Liu N; Wei L; Huang L; Yu F; Zheng W; Qin B; Zhu DQ; Morris-Natschke SL; Jiang S; Chen CH; Lee KH; Xie L
    J Med Chem; 2016 Apr; 59(8):3689-704. PubMed ID: 27070547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-like property-driven optimization of 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitors against rilpivirine-resistant mutant virus.
    Wei L; Wang HL; Huang L; Chen CH; Morris-Natschke SL; Lee KH; Xie L
    Bioorg Med Chem Lett; 2017 Jun; 27(12):2788-2792. PubMed ID: 28465101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis, and preclinical evaluations of novel 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) drug candidates.
    Sun LQ; Zhu L; Qian K; Qin B; Huang L; Chen CH; Lee KH; Xie L
    J Med Chem; 2012 Aug; 55(16):7219-29. PubMed ID: 22856541
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physicochemical property-driven optimization of diarylaniline compounds as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
    Liu N; Qin B; Sun LQ; Yu F; Lu L; Jiang S; Lee KH; Xie L
    Bioorg Med Chem Lett; 2014 Aug; 24(16):3719-23. PubMed ID: 25042339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimization of 2,4-diarylanilines as non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Sun LQ; Qin B; Huang L; Qian K; Chen CH; Lee KH; Xie L
    Bioorg Med Chem Lett; 2012 Apr; 22(7):2376-9. PubMed ID: 22406117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rilpivirine and Doravirine Have Complementary Efficacies Against NNRTI-Resistant HIV-1 Mutants.
    Smith SJ; Pauly GT; Akram A; Melody K; Ambrose Z; Schneider JP; Hughes SH
    J Acquir Immune Defic Syndr; 2016 Aug; 72(5):485-91. PubMed ID: 27124362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rilpivirine resistance mutation E138K in HIV-1 reverse transcriptase predisposed by prevalent polymorphic mutations.
    Hayashida T; Hachiya A; Ode H; Nishijima T; Tsuchiya K; Sugiura W; Takiguchi M; Oka S; Gatanaga H
    J Antimicrob Chemother; 2016 Oct; 71(10):2760-6. PubMed ID: 27330069
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cryo-EM structures of wild-type and E138K/M184I mutant HIV-1 RT/DNA complexed with inhibitors doravirine and rilpivirine.
    Singh AK; De Wijngaert B; Bijnens M; Uyttersprot K; Nguyen H; Martinez SE; Schols D; Herdewijn P; Pannecouque C; Arnold E; Das K
    Proc Natl Acad Sci U S A; 2022 Jul; 119(30):e2203660119. PubMed ID: 35858448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of MK-1439, an orally bioavailable non-nucleoside reverse transcriptase inhibitor potent against a wide range of resistant mutant HIV viruses.
    Côté B; Burch JD; Asante-Appiah E; Bayly C; Bédard L; Blouin M; Campeau LC; Cauchon E; Chan M; Chefson A; Coulombe N; Cromlish W; Debnath S; Deschênes D; Dupont-Gaudet K; Falgueyret JP; Forget R; Gagné S; Gauvreau D; Girardin M; Guiral S; Langlois E; Li CS; Nguyen N; Papp R; Plamondon S; Roy A; Roy S; Seliniotakis R; St-Onge M; Ouellet S; Tawa P; Truchon JF; Vacca J; Wrona M; Yan Y; Ducharme Y
    Bioorg Med Chem Lett; 2014 Feb; 24(3):917-22. PubMed ID: 24412110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways.
    Feng M; Wang D; Grobler JA; Hazuda DJ; Miller MD; Lai MT
    Antimicrob Agents Chemother; 2015 Jan; 59(1):590-8. PubMed ID: 25385110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting the entrance channel of NNIBP: Discovery of diarylnicotinamide 1,4-disubstituted 1,2,3-triazoles as novel HIV-1 NNRTIs with high potency against wild-type and E138K mutant virus.
    Tian Y; Liu Z; Liu J; Huang B; Kang D; Zhang H; De Clercq E; Daelemans D; Pannecouque C; Lee KH; Chen CH; Zhan P; Liu X
    Eur J Med Chem; 2018 May; 151():339-350. PubMed ID: 29635166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Resistance profile of rilpivirine].
    Imaz A; García F; di Yacovo S; Llibre JM
    Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():36-43. PubMed ID: 24252532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequent cross-resistance to rilpivirine among subtype C HIV-1 from first-line antiretroviral therapy failures in South Africa.
    Penrose KJ; Brumme CJ; Scoulos-Hanson M; Hamanishi K; Gordon K; Viana RV; Wallis CL; Harrigan PR; Mellors JW; Parikh UM
    Antivir Chem Chemother; 2018; 26():2040206618762985. PubMed ID: 29566538
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diarylaniline derivatives as a distinct class of HIV-1 non-nucleoside reverse transcriptase inhibitors.
    Qin B; Jiang X; Lu H; Tian X; Barbault F; Huang L; Qian K; Chen CH; Huang R; Jiang S; Lee KH; Xie L
    J Med Chem; 2010 Jul; 53(13):4906-16. PubMed ID: 20527972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.
    Bunupuradah T; Ananworanich J; Chetchotisakd P; Kantipong P; Jirajariyavej S; Sirivichayakul S; Munsakul W; Prasithsirikul W; Sungkanuparph S; Bowonwattanuwong C; Klinbuayaem V; Petoumenos K; Hirschel B; Bhakeecheep S; Ruxrungtham K
    Antivir Ther; 2011; 16(7):1113-21. PubMed ID: 22024527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minority variants associated with resistance to HIV-1 nonnucleoside reverse transcriptase inhibitors during primary infection.
    Nicot F; Saliou A; Raymond S; Sauné K; Dubois M; Massip P; Marchou B; Delobel P; Izopet J
    J Clin Virol; 2012 Oct; 55(2):107-13. PubMed ID: 22818969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2,6-Di(arylamino)-3-fluoropyridine Derivatives as HIV Non-Nucleoside Reverse Transcriptase Inhibitors.
    Sergeyev S; Yadav AK; Franck P; Michiels J; Lewi P; Heeres J; Vanham G; Ariën KK; Vande Velde CM; De Winter H; Maes BU
    J Med Chem; 2016 Mar; 59(5):1854-68. PubMed ID: 26785139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies.
    Anta L; Llibre JM; Poveda E; Blanco JL; Alvarez M; Pérez-Elías MJ; Aguilera A; Caballero E; Soriano V; de Mendoza C;
    AIDS; 2013 Jan; 27(1):81-5. PubMed ID: 22842995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Slow-, tight-binding HIV-1 reverse transcriptase non-nucleoside inhibitors highly active against drug-resistant mutants.
    Cancio R; Mai A; Rotili D; Artico M; Sbardella G; Clotet-Codina I; Esté JA; Crespan E; Zanoli S; Hübscher U; Spadari S; Maga G
    ChemMedChem; 2007 Apr; 2(4):445-8. PubMed ID: 17323401
    [No Abstract]   [Full Text] [Related]  

  • 20. Diphenyl ether non-nucleoside reverse transcriptase inhibitors with excellent potency against resistant mutant viruses and promising pharmacokinetic properties.
    Sweeney ZK; Kennedy-Smith JJ; Wu J; Arora N; Billedeau JR; Davidson JP; Fretland J; Hang JQ; Heilek GM; Harris SF; Hirschfeld D; Inbar P; Javanbakht H; Jernelius JA; Jin Q; Li Y; Liang W; Roetz R; Sarma K; Smith M; Stefanidis D; Su G; Suh JM; Villaseñor AG; Welch M; Zhang FJ; Klumpp K
    ChemMedChem; 2009 Jan; 4(1):88-99. PubMed ID: 19006142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.